Relationship among 201Tl uptake, nuclear DNA content and clinical behavior in metastatic thyroid carcinoma

Journal of Nuclear Medicine

Volumn 40, Issue 6, 1999, Pages 963-967

  Nakada, Kunihiro ^a,b   Katoh, Chietsugu ^a   Morita, Koichi ^a   Kanegae, Kakuko ^a   Tsukamoto, Eriko ^a   Shiga, Tooru ^a   Mochizuki, Takafumi ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

201Tl; DNA content; Flow cytometry; Thyroid carcinoma

Indexed keywords

DNA; THALLIUM 201; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; THALLIUM;

ADULT; AGED; ANEUPLOIDY; ARTICLE; DIPLOIDY; DNA CONTENT; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID SCINTISCANNING; ADENOCARCINOMA; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; HEAD AND NECK TUMOR; MEDIASTINUM TUMOR; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SCINTISCANNING; THYROID GLAND; THYROID TUMOR; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ANEUPLOIDY; CARCINOMA, PAPILLARY; CHI-SQUARE DISTRIBUTION; DIPLOIDY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; THALLIUM RADIOISOTOPES; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0032587183     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.
2. Hay ID, Grant CS, Taylor WE, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic system. Surgery. 1987;102:1088-1095.
3. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
4. Bäckdahl M, Auer G, Forsslund G. Prognostic value of nuclear DNA content in follicular thyroid tumors. Acta Chir Scand. 1986;152:1-7.
5. Joensuu H, Klemi P, Eerola E, Tuominen J. Influence of cellular DNA content on survival in differentiated thyroid cancer. Cancer. 1986;58:2462-2467.
6. Bäckdahl M, Carstensen J, Auer G, Tallroth E. Statistical evaluation of the prognostic value of nuclear DNA content in papillary, follicular, and medullary thyroid tumors. World J Surg. 1986;10:974-980.
7. Hrafnkelsson J, Stål O, Eneström S, et al. Cellular DNA pattern, S-phase frequency, and survival in papillary thyroid cancer. Acta Oncol. 1988;27:329-333.
8. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab North Am. 1990;19:545-576.
9. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content: the AMES risk-group classification for papillary thyroid cancer. Surgery. 1992;112: 1154-1160.
10. O'Doherty MJ, Nunan TO, Croft DN. Radionuclides and therapy of thyroid cancer. Nucl Med Commun. 1993;14:736-755.
11. 201TI scintigraphy in proliferative activity in thyroid neoplasms. Ann Nucl Med. 1996;10:41-48.
12. Kume N, Suga K, Nishiguchi K, Camaro M, Matsunaga N. Relationship between thallium-201 and tumor proliferative activity in thyroid nodules. Eur J Nucl Med. 1996;23:376-382.
13. Nakada K, Katoh C, Kanegae K, et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy. J Nucl Med. 1998;39:807-810.
14. Isobe H, Itoh M, Shimizu T, et al. Analysis of nuclear DNA content in primary lung cancer cells by means of flow cytometry [in Japanese]. Haigan. 1987;27:125-132.
15. Barogie B, Drewinko B. Schumann J, et al. Cellular DNA content as a marker of neoplasia in man. Am J Med. 1980;69:195-203.
16. Hoefanagel CA, Delprat CC, Marcuse HR, de Vijlder JJM. Role of thallium-201 total body scintigraphy in follow up of thyroid carcinoma. J Nucl Med. 1986;27:1854-1857.
17. Brrendel AJ, Guyot M, Jeandot R, Lefort G, Manciet G. Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med. 1988;29:1515-1520.
18. Rammana L, Waxman A, Braustein G. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med. 1991;32:441-446.
19. Charkes ND, Vitti RA, Brooks K. Thallium-201 SPECT increases detectability of thyroid cancer metastases. J Nucl Med. 1990;31:147-153.
20. Dadparvr S, Krishna L, Brady LW, et al. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer. 1993;71:3763-3773.
21. Carril JM, Ouirce R, Serrano J, et al. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med. 1997;38:68 6-692.
22. Takekawa H, Takaoka K, Tsukamoto E, Kanegae K, Miller F, Kawakami Y. Thallium-201 single photon emission computed tomography as an indicator of prognosis for patients with lung carcinoma. Cancer. 1997;80:198-203.
23. Johnson TL, Lloyd RV, Thompson NW, Bierwalles WH, Sisson JC. Prognostic implications of tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1998;12:22-26.
24. Wenig BM, Thompson LD, Adair CF, Scmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer. 1998;85:740-753.
25. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V, Werber J. Changing clinical, pathological, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg. 1976;184:541-553.
26. Tennvall J, Björklund A, Moller T, Ranstam J, Akerman M. Prognostic factors of papillary, follicular and medullary carcinomas of the thyroid gland. Retrospective analysis of 216 patients with a median follow-up of 11 years. Acta Radiol Oncol. 1985;24:17-24.
27. Siperstein AE, Zeng OH, Gum ET, Levin KE, Clark OH. Adenyl cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg. 1988;12:528-533.
28. Haugen BR, Nawaz S, Markham N, et al. Telomerase activity in benign and malignant thyroid tumors. Thyroid. 1997;7:337-342.
29. Okayasu I, Osakabe T, Fujiwara M, Fukuda H, Kato M, Oshimura M. Significant correlation of telomerase activity in thyroid papillary carcinomas with cell differentiation, proliferation and extrathyroidal extension [in Japanese]. Jpn J Cancer Res. 1997;88:965-970.
30. Harber RS, Weiser KR, Pritsker A, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid. 1997;7: 363-367.
31. Barlogie B, Johonston DA, Smallwood L, et al. Prognostic implications of ploidy and proliferative activity in human solid tumors. Cancer Genet Cytogenet. 1982;6:17-28.
32. Barlogie B, Raber M, Schuman J, et al. Flow cytometry in clinical cancer research. Cancer Res. 1983;43:3982-3997.
33. 67Ga scanning in the diagnosis of anaplastic carcinoma and malignant lymphoma of the thyroid. Radiology. 1981;141:491-497.
34. Higashi T, Watanabe M, Yamaguchi T, et al. The relationship between Ga-67 uptake and nuclear DNA Feulgen content in thyroid tumors: concise communication. J Nucl Med. 1982;23:988-992.
35. Klemi PJ, Joensuu H, Eerola E. DN A aneuploidy in anaplastic carcinoma of the thyroid gland. Am J Clin Pathol. 1988;89:154-159.
36. Larson SM. Rasely JS, Allen DR, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst. 1980;64: 41-53.
37. Larson SM. The role of transferrins in gallium uptake. Int J Nucl Med Biol. 1981;8:257-266.
38. +) activated ATPase of rabbit kidney. Biochim Biophys Acta. 1968;159:160-166.
39. Takekawa H, Itoh K, Abe S, et al. Thallium-201 uptake, histopathological differentiation and NA-K ATPase in lung adenocarcinoma. J Nucl Med. 1996;37: 955-958.
40. Kishida T. Mechanisms of thallium-201 accumulation in the thyroid gland-clinical usefulness of dynamic study in thallium-201 chloride for the differential diagnosis of thyroid nodules. Kaku Igaku Jpn J Nucl Med. 1987;24:991-1004.
41. Sandrock D, Merino MJ, Norton A, Neumann RD. Ultrastructural histology correlated with results of thallium-201/technetium-99m parathyroid subtraction scintigraphy, J Nucl Med. 1993;34:24-29.
42. Higashi T, Wakao H, Yamaguchi M, Suga K. The relationship between Ga-67 accumulation and cell cycle in malignant tumor cell cycle. Eur J Nucl Med. 1988;14:155-158.
43. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1995;23:312-319.
44. 18F] fluorodeoxy glucose positron emission tomography. Nucl Med Commun. 1998;19:547-554.
45. Slosman DO, Pugin J. Lack of correlation between tritiated deoxyglucose, thalium-201 and techetium-99m MIBI cell incorporation under various cell stresses. J Nucl Med. 1994;35:120-126.
46. Oriuchi N, Tomiyama K, Inoue T, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med. 1996;37: 457-462.
47. Higashi K, Nishikawa T, Seki H, et al. Comparisons of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med. 1998;39:9-15.